Marizomib suppresses triple-negative breast cancer via proteasome and oxidative phosphorylation inhibition

Conclusions: Our data provide a strong rationale for a clinical evaluation of marizomib in primary and metastatic TNBC patients.

Source: Theranostics - July 3, 2020 Category: Molecular Biology Authors: Prahlad V. Raninga, Andy Lee, Debottam Sinha, Lan-feng Dong, Keshava K. Datta, Xue Lu, Priyakshi Kalita-de Croft, Mriga Dutt, Michelle Hill, Normand Pouliot, Harsha Gowda, Murugan Kalimutho, Jiri Neuzil, Kum Kum Khanna Tags: Research Paper Source Type: research